Lisa Anson, Redx Pharma CEO
March 8, 2023 07:18 AM ESTUpdated 02:48 PM
R&D

With PhII fail, Redx Phar­ma scraps monother­a­py bil­iary can­cer de­vel­op­ment for lead pro­gram

Katherine Lewin

News Reporter

UK biotech Redx Phar­ma’s lead drug has failed a Phase II study for bil­iary tract can­cer, and the re­sults are “not suf­fi­cient” to con­tin­ue de­vel­op­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times